Table 2 Studies calculating the cost of adverse drug events, clinical data
From: Evaluating the costs of adverse drug events in hospitalized patients: a systematic review
N° | First author (year) (ref) | Country | Clinical area | Study design | Number of patients | Type of ADE | Population Settings | Suspected drug(s) |
|---|---|---|---|---|---|---|---|---|
1 | Katsuno et al. (2021) [19] | Japan | Inpatients and outpatients | - observational - monocentric - retrospective | 359 | ADE | Patient aged > 1 year | All (except experimental drugs) |
2 | Trumbo et al. (2021) [8] | USA | Inpatients and outpatients | Pharmacovigilance database - observational - multicentric - retrospective | NK | ADE | All patients | Intravenous iron |
3 | Iwasaki et al. (2021) [18] | Japan | Inpatients (tertiary care hospital) | - observational - multicentric - retrospective | 907 | Preventable ADE | Patients < 15 years and hospitalised in any unit and patients over 15 years old hospitalised in paediatric units | All prescribed medication |
4 | Tissot et al. (2021) [9] | France | Inpatients and outpatients | Pharmacovigilance database - observational - multicentric - retrospective | 1185 | Serious ADR | All patients except patients with serious congenital anomalies related | All |
5 | Maity et al. (2021) [10] | Canada | Inpatients | Pharmacovigilance database - observational - multicentric - retrospective | 63 069 | ADR | All patients | Remicad® and Humira® (biosimilars were not included) |
6 | Knight et al. (2019) [11] | South Africa | Inpatients (tertiary care hospital) | - observational - monocentric - retrospective | 89 | ADR | All patients with drug sensitive tuberculosis with a suspected cutaneous adverse drug reaction to first line anti-tuberculosis drugs | First line anti-tuberculosis drugs |
7 | Boostani et al. (2019) [20] | Iran | Inpatients (tertiary care hospital / internal medicine unit) | - observational - monocentric - prospective | 100 | ME | Patients hospitalised in internal medicine ward | All |
8 | Riaz et al. (2019) [16] | USA | Inpatients (tertiary care hospital) | - observational - multicentric - retrospective | 3 832 322 | ADE | Age 65 and above | All |
9 | Beck et al. (2019) [12] | USA | Inpatients (emergency room and tertiary care) | - observational - monocentric - retrospective | 430 | ADR | Patients under 21 | Antibiotics |
10 | Lee et al. (2019) [21] | Korea | Inpatients (emergency room and tertiary care) | - observational - multicentric - retrospective | 903 | ADR | All patients | All |
11 | Liao et al. (2019) [17] | Taiwan | Inpatients (tertiary care hospital) | - observational - monocentric - retrospective | 2 393 | ADR | Age 65 and above | All |
12 | Pok et al. (2018) [14] | Malaysia | Inpatients (tertiary care hospital/ rheumatology unit) | - observational - multicentric - retrospective | 634 | ADE | Patient hospitalised in the rheumatology department with osteoarthritis or rheumatoid arthritis | NSAID |
13 | Schnippel et al. (2018) [13] | South Africa | Inpatients | - observational - multicentric - retrospective | 12 527 | ADR | Multi drugs resistant (+ rifampicin) tuberculosis patients | Drugs used in rifampicin-resistant tuberculosis |
14 | Shafi et al. (2018) [15] | USA | Inpatients (tertiary care hospital/ Surgery and endoscopy unit) | - observational - multicentric - retrospective | 135 379 | ADE | Age 18 and above (patients having surgery or endoscopy) | Opioids |
15 | Kurle et al. (2018) [22] | India | Inpatients (tertiary care hospital / dermatology unit) | - observational - monocentric - prospective | 55 | ADR | All patients except patients using alternative therapies | All |
16 | Slight et al. (2018) [23] | USA | Inpatients (tertiary care hospital) | - observational - monocentric - retrospective | 40 990 | Preventable ADE | All patients | All |
17 | Gyllensten et al. (2017) [24] | Sweden | Inpatients and outpatients | - observational - multicentric - retrospective | 4 970 | ADE | Age 18 and above and living in the Östergötland county, Sweden | All |
18 | Natanaelsson et al. (2017) [25] | Sweden | Inpatients and outpatients | - observational - multicentric - retrospective | 5 025 | ADE | Age 18 and above and living in the Östergötland county, Sweden | All |
19 | McCarthy Jr. et al. (2017) [26] | USA | Inpatients (tertiary care hospital) | - observational - monocentric - retrospective | 3 521 | ADE | All patients | All |
20 | Spector et al. (2017) [27] | USA | Inpatients (tertiary care hospital) | - observational - multicentric - retrospective | 85 338 | ADE | Age 18 and above | Anticoagulants and Hypoglycaemic agents |